Arvinas, Inc.
NASDAQ:ARVN
7.94 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Arvinas, Inc. |
| Symbool | ARVN |
| Munteenheid | USD |
| Prijs | 7.94 |
| Beurswaarde | 582,935,744 |
| Dividendpercentage | 0% |
| 52-weken bereik | 5.9 - 29.61 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. John G. Houston Ph.D. |
| Website | https://www.arvinas.com |
An error occurred while fetching data.
Over Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









